Log In
Print
BCIQ
Print
Print this Print this
 

OGX-225

  Manage Alerts
Collapse Summary General Information
Company OncoGenex Pharmaceuticals Inc.
DescriptionSecond-generation antisense inhibitor of insulin-like growth factor-2 (IGF-2) receptor (IGF2R) and insulin-like growth factor (IGF) binding protein 5 (IGFBP5)
Molecular Target Insulin-like growth factor (IGF) binding protein 2 (IGFBP2) ; Insulin-like growth factor (IGF) binding protein 5 (IGFBP5)
Mechanism of ActionAntisense therapy
Therapeutic ModalityNucleic acid: Linear RNA: Antisense
Latest Stage of DevelopmentPreclinical
Standard IndicationSolid tumors
Indication DetailsTreat solid tumors
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today